Journal
PLOS ONE
Volume 5, Issue 12, Pages -Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0015686
Keywords
-
Categories
Funding
- National Institutes of Health (NIH), National Cancer Institute, Center for Cancer Research [CA128616]
- Howard Hughes Medical Institute-NIH
Ask authors/readers for more resources
Amyloid-beta interacts with two cell surface receptors, CD36 and CD47, through which the matricellular protein thrombospondin-1 inhibits soluble guanylate cyclase activation. Here we examine whether amyloid-beta shares this inhibitory activity. Amyloid-beta inhibited both drug and nitric oxide-mediated activation of soluble guanylate cyclase in several cell types. Known cGMP-dependent functional responses to nitric oxide in platelets and vascular smooth muscle cells were correspondingly inhibited by amyloid-beta. Functional interaction of amyloid-beta with the scavenger receptor CD36 was indicated by inhibition of free fatty acid uptake via this receptor. Both soluble oligomer and fibrillar forms of amyloid-beta were active. In contrast, amyloid-beta did not compete with the known ligand SIRP alpha for binding to CD47. However, both receptors were necessary for amyloid-beta to inhibit cGMP accumulation. These data suggest that amyloid-beta interaction with CD36 induces a CD47-dependent signal that inhibits soluble guanylate cyclase activation. Combined with the pleiotropic effects of inhibiting free fatty acid transport via CD36, these data provides a molecular mechanism through which amyloid-beta can contribute to the nitric oxide signaling deficiencies associated with Alzheimer's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available